Evidence map›Paper›PMID 34582343›Full record

ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2022

Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma.

Eoghan R Malone, Hao-Wen Sim, Audrius Stundzia, Sacha Pierre, Ur Metser, Martin O'Malley, Adrian G Sacher, Srikala S Sridhar, Aaron R Hansen

Abstract read
In one paragraph

Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Eoghan R MaloneDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, UHN, Toronto, ON, Canada.
Hao-Wen SimDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, UHN, Toronto, ON, Canada.
Audrius StundziaTomographix IP Ltd., Toronto, ON, Canada.
Sacha PierreDivision of Abdominal Imaging, Joint Department of Medical Imaging, University of Toronto, Toronto, ON, Canada.
Ur MetserDivision of Molecular Imaging, Joint Department of Medical Imaging, University of Toronto, Toronto, ON, Canada.
Martin O'MalleyDivision of Abdominal Imaging, Joint Department of Medical Imaging, University of Toronto, Toronto, ON, Canada.
Adrian G SacherDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, UHN, Toronto, ON, Canada.
Srikala S SridharDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, UHN, Toronto, ON, Canada.
Aaron R HansenDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, UHN, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe anti-programmed cell death protein-1 (PD-1) immune checkpoint inhibitor nivolumab is currently approved for the treatment of patients with metastatic renal cell carcinoma (mRCC); approximately 25% of patients respond. We hypothesized that we could identify a biomarker of response using radiomics to train a machine learning classifier to predict nivolumab response outcomes.

methodsPatients with mRCC of different histologies treated with nivolumab in a single institution between 2013 and 2017 were retrospectively identified. Patients were labelled as responders (complete response [CR]/partial response [PR]/durable stable disease [SD]) or non-responders based on investigator tumor assessment using RECIST 1.1 criteria. For each patient, lesions were contoured from pre-treatment and first post-treatment computed tomography (CT) scans. This information was used to train a radial basis function support vector machine classifier to learn a prediction rule to distinguish responders from non-responders. The classifier was internally validated by a 10-fold nested cross-validation.

resultsThirty-seven patients were identified; 27 (73%) met the inclusion criteria. One hundred and four lesions were contoured from these 27 patients. The median patient age was 56 years, 78% were male, 89% had clear-cell histology, 89% had prior nephrectomy, and 89% had prior systemic therapy. There were 19 responders vs. eight non-responders. The lesions selected were lymph nodes (60%), lung metastases (23%), and renal/adrenal metastases (17%). For the classifier trained on the baseline CT scans, 69% accuracy was achieved. For the classifier trained on the first post-treatment CT scans, 66% accuracy was achieved.

conclusionsThe set of radiomic signatures was found to have limited ability to discriminate nivolumab responders from non-responders. The use of novel texture features (two-point correlation measure, two-point cluster measure, and minimum spanning tree measure) did not improve performance.

Identifiers

PMID34582343
PMCPMC8932415

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.